Septerna, Inc.
SEPNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeSepterna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and. The $1.35B market capitalization puts SEPN squarely in small-cap range for its industry. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
Market Cap
$1.35B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-11.26
EPS (TTM)
$-0.80
EPS (Fwd)
$-2.66
ROE
-9.3%
ROA
-8.5%
Cash
$347.4M
Total Debt
$23.1M
Free CF
$24.0M
52W Change
200.3%
Annual Financials
Cash vs Debt
With $347.4M in cash and $23.1M in debt, SEPN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $24.0M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -9.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, SEPN has financial flexibility that may help navigate uncertain periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SEPN.